Citation: Y. Kalechman et al., DELAY IN THE ONSET OF SLE FOLLOWING TREATMENT WITH THE IMMUNOMODULATOR AS101 - ASSOCIATION WITH IL-10 INHIBITION AND INCREASE IN TNF-ALPHA LEVELS, European cytokine network, 9(3), 1998, pp. 45-45
Authors:
KALECHMAN Y
STRASSMANN G
ALBECK M
SREDNI B
Citation: Y. Kalechman et al., UP-REGULATION BY AMMONIUM TRICHLORO(DIOXOETHYLENE-0,0')TELLURATE (AS101) OF FAS APO-1 EXPRESSION ON B16 MELANOMA-CELLS - IMPLICATIONS FOR THE ANTITUMOR EFFECTS OF AS101/, The Journal of immunology (1950), 161(7), 1998, pp. 3536-3542
Citation: A. Albeck et al., TELLURIUM COMPOUNDS - SELECTIVE-INHIBITION OF CYSTEINE PROTEASES AND MODEL REACTION WITH THIOLS, Inorganic chemistry, 37(8), 1998, pp. 1704-1712
Authors:
ROSENBLATTBIN H
KALECHMAN Y
VONSOVER A
XU RH
DA JP
SHALIT F
HUBERMAN M
KLEIN A
STRASSMANN G
ALBECK M
SREDNI B
Citation: H. Rosenblattbin et al., THE IMMUNOMODULATOR AS101 RESTORES T-H1 TYPE OF RESPONSE SUPPRESSED BY BABESIA-RODHAINI IN BALB C MICE/, Cellular immunology (Print), 184(1), 1998, pp. 12-25
Citation: Y. Kalechman et al., SUPPRESSION OF INTERLEUKIN-10 BY THE IMMUNOMODULATOR AS101 INHIBITS DEVELOPMENT OF AUTOANTIBODIES AND GLOMERULONEPHRITIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE), Journal of the American Society of Nephrology, 8, 1997, pp. 2503-2503
Citation: Y. Kalechman et al., MECHANISM OF THE ANTITUMOR EFFECT OF THE IMMUNOMODULATOR AS101 AND PREVENTION BY AS101 OF BONE-MARROW TOXICITY WHEN ADMINISTERED WITH TAXOL, Experimental hematology, 25(8), 1997, pp. 550-550
Authors:
KALECHMAN Y
GAFTER U
DA JP
ALBECK M
ALARCONSEGOVIA D
SREDNI B
Citation: Y. Kalechman et al., DELAY IN THE ONSET OF SYSTEMIC LUPUS-ERYTHEMATOSUS FOLLOWING TREATMENT WITH THE IMMUNOMODULATOR AS101 - ASSOCIATION WITH IL-10 INHIBITION AND INCREASE IN TNF-ALPHA LEVELS, The Journal of immunology, 159(6), 1997, pp. 2658-2667
Authors:
SREDNI B
TICHLER T
SHANI A
CATANE R
KAUFMAN B
STRASSMANN G
ALBECK M
KALECHMAN Y
Citation: B. Sredni et al., PREDOMINANCE OF TH1 RESPONSE IN TUMOR-BEARING MICE AND CANCER-PATIENTS TREATED WITH AS101, Journal of the National Cancer Institute, 88(18), 1996, pp. 1276-1284
Authors:
XU RH
KALECHMAN Y
ALBECK M
KUNG HF
SREDNI B
Citation: Rh. Xu et al., INHIBITION OF B16 MELANOMA METASTASIS BY THE IMMUNOMODULATOR AS101, International journal of oncology, 9(2), 1996, pp. 319-325
Citation: Ks. Olsen et al., THE EFFECT OF KETANSERIN ON ICP AND CBF IN PATIENTS WITH NORMAL-PRESSURE HYDROCEPHALUS, Journal of neurosurgical anesthesiology, 8(3), 1996, pp. 216-219
Authors:
SREDNI B
TICHLER T
SHANI A
SHAPIRA J
BRUDERMAN I
ALBECK M
KALECHMAN Y
Citation: B. Sredni et al., BONE-MARROW SPARING AND PREVENTION OF ALOPECIA BY AS101 IN A RANDOMIZED PHASE-II STUDY ON NSCL CANCER-PATIENTS TREATED WITH CARBOPLATIN ANDETOPOSIDE, Experimental hematology, 24(9), 1996, pp. 351-351
Authors:
KALECHMAN Y
TICHLER T
SHANI A
ALBECK M
SREDNI B
Citation: Y. Kalechman et al., DIFFERENTIAL EFFECT OF THE IMMUNOMODULATOR AS101 ON B7-1 AND B7-2 COSTIMULATORY MOLECULES - ROLE IN TH1 PREDOMINANCE AND IN THE ANTITUMORALEFFECTS OF AS101, Experimental hematology, 24(9), 1996, pp. 392-392
Authors:
KALECHMAN Y
SHANI A
DOVRAT S
WHISNANT JK
METTINGER K
ALBECK M
SREDNI B
Citation: Y. Kalechman et al., THE ANTITUMORAL EFFECT OF THE IMMUNOMODULATOR AS101 AND PACLITAXEL (TAXOL) IN A MURINE MODEL OF LUNG ADENOCARCINOMA, The Journal of immunology, 156(3), 1996, pp. 1101-1109
Authors:
SREDNI B
XU RH
ALBECK M
GAFTER U
GAL R
SHANI A
TICHLER T
SHAPIRA J
BRUDERMAN I
CATANE R
KAUFMAN B
WHISNANT JK
METTINGER KL
KALECHMAN Y
Citation: B. Sredni et al., THE PROTECTIVE ROLE OF THE IMMUNOMODULATOR AS101 AGAINST CHEMOTHERAPY-INDUCED ALOPECIA STUDIES ON HUMAN AND ANIMAL-MODELS, International journal of cancer, 65(1), 1996, pp. 97-103
Citation: Rh. Xu et al., THE CYTOPROTECTIVE EFFECT OF THE IMMUNOMODULATOR AS101 AGAINST HYDROCHLORIDE INDUCED GASTRIC-LESIONS, Research communications in molecular pathology and pharmacology, 87(1), 1995, pp. 4-20
Authors:
SREDNI B
ALBECK M
TICHLER T
SHANI A
SHAPIRA J
BRUDERMAN I
CATANE R
KAUFMAN B
KALECHMAN Y
Citation: B. Sredni et al., BONE MARROW-SPARING AND PREVENTION OF ALOPECIA BY AS1O1 IN NON-SMALL-CELL LUNG-CANCER PATIENTS TREATED WITH CARBOPLATIN AND ETOPOSIDE, Journal of clinical oncology, 13(9), 1995, pp. 2342-2353
Authors:
KALECHMAN Y
SHANI A
DOVRAT S
ALBECK M
BRUCKNER HW
SREDNI B
Citation: Y. Kalechman et al., SYNERGISTIC ANTITUMOR EFFECT OF THE IMMUNOMODULATOR ASIOI AND TAXOL IN EXPERIMENTAL MURINE MODEL, Experimental hematology, 23(8), 1995, pp. 799-799
Authors:
SREDNI B
SHANI A
SHAPIRA J
BRUDERMAN I
ALBECK M
KALECHMAN Y
TICHLER T
Citation: B. Sredni et al., BONE-MARROW SPARING AND PREVENTION OF ALOPECIA BY ASIOI IN A RANDOMIZED PHASE-II STUDY ON NSCL CANCER-PATIENTS TREATED WITH CARBOPLATIN ANDVP-16, Experimental hematology, 23(8), 1995, pp. 858-858
Authors:
KALECHMAN Y
RUSHKIN G
NERUBAY J
ALBECK M
SREDNI B
Citation: Y. Kalechman et al., EFFECT OF THE IMMUNOMODULATOR AS101 ON CHEMOTHERAPY-INDUCED MULTILINEAGE MYELOSUPPRESSION, THROMBOCYTOPENIA, AND ANEMIA IN MICE, Experimental hematology, 23(13), 1995, pp. 1358-1366
Citation: Y. Kalechman et al., INDUCTION OF ACUTE-PHASE PROTEINS IN MICE AND HUMANS BY TREATMENT WITH AS101, AN IMMUNOMODULATOR WITH RADIOPROTECTIVE PROPERTIES, Immunopharmacology, 29(2), 1995, pp. 149-158
Authors:
KALECHMAN Y
ZULOFF A
ALBECK M
STRASSMANN G
SREDNI B
Citation: Y. Kalechman et al., ROLE OF ENDOGENOUS CYTOKINES SECRETION IN RADIOPROTECTION CONFERRED BY THE IMMUNOMODULATOR AMMONIUM TRICHLORO(DIOXYETHYLENE-0-0')TELLURATE, Blood, 85(6), 1995, pp. 1555-1561
Citation: B. Sredni et al., THE ROLE OF INTERLEUKIN-1 (IL-1), TUMOR-NECROSIS-FACTOR (TNF) AND INTERLEUKIN-6 (IL-6) IN THE RADIOPROTECTIVE PROPERTIES EXERTED BY AMMONIUM TRICHLORO(DIOXYETHYLENE-O-O')TELLURATE (AS101), Experimental hematology, 22(8), 1994, pp. 684-684